Miyahira AK, Soule HR. The history of prostate-specific membrane antigen as a theranostic target in prostate cancer: the cornerstone role of the prostate cancer foundation. J Nucl Med. 2022;63(3):331–8. https://doi.org/10.2967/jnumed.121.262997.Accessed2022-12-21.

Article  CAS  PubMed  Google Scholar 

Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Schlenkhoff CD, Gärtner F, Rogenhofer S, Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477.

Article  PubMed  PubMed Central  Google Scholar 

Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170–6. https://doi.org/10.2967/jnumed.115.171397.Accessed2022-12-15.

Article  CAS  PubMed  Google Scholar 

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee S-T, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID, Azad AA, Chua W, Davis ID, Dhiantravan N, Emmett L, Ford K, Hofman MS, Francis RJ, Gedye C, Goh JC, Guminski A, Hsiao E, Iravani A, Joshua AM, Kirkwood ID, Langford A, Lawrence N, Lee S-T, Lin P, Martin AJ, McDonald W, McJannett MM, Ng S, Pattison DA, Ramdave S, Rana N, Redfern AD, Rutherford NK, Sandhu S, Scott AM, Stockler MR, Subramaniam S, Tan TH, Violet JA, Weickhardt A, Williams SG, Yip S, Zhang AY. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804. https://doi.org/10.1016/S0140-6736(21)00237-3.Accessed2022-12-15.

Article  CAS  PubMed  Google Scholar 

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Fendler WP, Krause BJ. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.

Article  CAS  PubMed  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322.Accessed2022-12-20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Bolton RCD, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester H-J, Bodei L, Fanti S, Haberkorn U, Herrmann K. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–44.

Article  PubMed  Google Scholar 

Paganelli G, Sarnelli A, Severi S, Sansovini M, Belli ML, Monti M, Foca F, Celli M, Nicolini S, Tardelli E, Marini I, Matteucci F, Giganti M, Di Iorio V, De Giorgi U. Dosimetry and safety of 177lu psma-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(13):3008–17.

Article  CAS  PubMed  Google Scholar 

Zhang J, Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Langbein T, Baum RP. 177lu-psma-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney. J Nucl Med. 2019;60(11):1579–86.

Article  CAS  PubMed  Google Scholar 

Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, Bal C. Post-therapeutic dosimetry of 177lu-dkfz-psma-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Nucl Med Commun. 2017;38(1):91–8.

Article  PubMed  Google Scholar 

Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ, Hofman MS. Dosimetry of 177lu-psma-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517–23.

Article  CAS  PubMed  Google Scholar 

Vergnaud L, Giraudet A-L, Moreau A, Salvadori J, Imperiale A, Baudier T, Badel J-N, Sarrut D. Patient-specific dosimetry adapted to variable number of spect/ct time-points per cycle for 177lu-dotatate therapy. EJNMMI Phys. 2022;9(1):37.

Article  PubMed  PubMed Central  Google Scholar 

Rosar F, Schön N, Bohnenberger H, Bartholomä M, Stemler T, Maus S, Khreish F, Ezziddin S, Schaefer-Schuler A. Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy. EJNMMI Phys. 2021;8(1):40. https://doi.org/10.1186/s40658-021-00385-4.Accessed2022-12-23.

Article  PubMed  PubMed Central  Google Scholar 

Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K. MIRD Pamphlet No. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151–62. https://doi.org/10.2967/jnumed.115.159012.

Article  CAS  PubMed  Google Scholar 

SjögreenGleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, Konijnenberg M, Cremonesi M, Verburg FA, Bernhardt P, Eberlein U, Gear J. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778–809. https://doi.org/10.1007/s00259-022-05727-7.Accessed2022-12-20.

Article  Google Scholar 

Beauregard J-M, Hofman MS, Pereira JM, Eu P, Hicks RJ. Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging. 2011;11(1):56–66. https://doi.org/10.1102/1470-7330.2011.0012.Accessed2021-07-23.

Article  PubMed  PubMed Central  Google Scholar 

Santoro L, Mora-Ramirez E, Trauchessec D, Chouaf S, Eustache P, Pouget JP, Kotzki PO, Bardiès M, Deshayes E. Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177lu-[dota0, tyr3]-octreotate. EJNMMI Res. 2018;8(103):1–13.

Google Scholar 

Sundlöv A, Gustafsson J, Brolin G, Mortensen N, Hermann R, Bernhardt P, Svensson J, Ljungberg M, Tennvall J, SjögreenGleisner K. Feasibility of simplifying renal dosimetry in 177lu peptide receptor radionuclide therapy. EJNMMI Phys. 2018;5(1):1–19.

Article  Google Scholar 

Ilan E, Sandström M, Wassberg C, Sundin A, Garske-Román U, Eriksson B, Granberg D, Lubberink M. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177lu-dotatate. J Nucl Med. 2015;56(2):177–82.

Article  PubMed  Google Scholar 

Takahashi Y, Miyagawa M, Nishiyama Y, Ishimura H, Mochizuki T. Performance of a semiconductor SPECT system: comparison with a conventional Anger-type SPECT instrument. Ann Nucl Med. 2013;27(1):11–6. https://doi.org/10.1007/s12149-012-0653-9.Accessed2022-05-24.

Article  CAS  PubMed  Google Scholar 

Ito T, Matsusaka Y, Onoguchi M, Ichikawa H, Okuda K, Shibutani T, Shishido M, Sato K. Experimental evaluation of the GE NM/CT 870 CZT clinical SPECT system equipped with WEHR and MEHRS collimator. J Appl Clin Med Phys. 2021;22(2):165–77. https://doi.org/10.1002/acm2.13158.Accessed2021-09-02.

Article  PubMed  PubMed Central  Google Scholar 

Ritt P. Recent Developments in SPECT/CT. Semin Nucl Med. 2022;52(3):276–85. https://doi.org/10.1053/j.semnuclmed.2022.01.004.Accessed2022-06-21.

Article  PubMed  Google Scholar 

Vaz SC, Oliveira F, Herrmann K, Veit-Haibach P. Nuclear medicine and molecular imaging advances in the 21st century. Br J Radiol. 2020;93(1110):20200095. https://doi.org/10.1259/bjr.20200095.

Article  PubMed  Google Scholar 

Song H, Ferri V, Duan H, Aparici CM, Davidzon G, Franc BL, Moradi F, Nguyen J, Shah J, Iagaru A. Spect at the speed of pet: a feasibility study of czt-based whole-body spect/ct in the post 177lu-dotatate and 177lu-psma617 setting. Eur J Nucl Med Mol Imaging. 2023;50:2250–7.

Article  CAS  PubMed  Google Scholar 

Goshen E, Beilin L, Stern E, Kenig T, Goldkorn R, Ben-Haim S. Feasibility study of a novel general purpose CZT-based digital SPECT camera: initial clinical results. EJNMMI Phys. 2018;5(1):6. https://doi.org/10.1186/s40658-018-0205-z.Accessed2021-07-17.

Article  PubMed  PubMed Central  Google Scholar 

Bordonne M, Chawki MB, Marie P-Y, Zaragori T, Roch V, Grignon R, Imbert L, Verger A. High-quality brain perfusion SPECT images may be achieved with a high-speed recording using 360° CZT camera. EJNMMI Phys. 2020;7(1):65. https://doi.org/10.1186/s40658-020-00334-7.Accessed2021-07-17.

Article  PubMed  PubMed Central  Google Scholar 

Imbert L, Perrin M, Claudin M, Boursier C, Marie P-Y. High quality attenuation-corrected myocardial perfusion images may be achieved in patients with morbid obesity using a whole-body CZT camera and a low-dose injection protocol. J Nucl Cardiol. 2020. https://doi.org/10.1007/s12350-020-02142-z.Accessed2021-07-21.

Article  PubMed  Google Scholar 

Desmonts C, Bouthiba MA, Enilorac B, Nganoa C, Agostini D, Aide N. Evaluation of a new multipurpose whole-body CzT-based camera: comparison with a dual-head Anger camera and first clinical images. EJNMMI Phys. 2020;7(1):18. https://doi.org/10.1186/s40658-020-0284-5.Accessed2021-07-17.

Article  PubMed  PubMed Central  Google Scholar 

Chevalier E, Boursier C, Claudin M, Marie P-Y, Imbert L. Feasibility of 177Lu therapy monitoring using fast whole-body SPECT recordings provided by a high-speed 360° CZT camera. Clin Nucl Med. 2020;45(11):493–4. https://doi.org/10.1097/RLU.0000000000003169.Accessed2022-07-04.

Article  Google Scholar 

Kennedy JA, Lugassi R, Gill R, Keidar Z. Digital solid-state spect/ct quantitation of absolute 177Lu radiotracer concentration: in vivo and in vitro validation. J Nucl Med. 2020;61(9):1381–7.

Article  CAS  PubMed  Google Scholar